Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.

Clinical pharmacology and therapeutics·2019

Same author

Regulatory watch: The orphan drug pipeline in Europe.

Nature reviews. Drug discovery·2016

Same author

Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union.

Orphanet journal of rare diseases·2015

Same author

Establishing medical plausibility in the context of orphan medicines designation in the European Union.

Orphanet journal of rare diseases·2014

Same author

Use of biomarkers in the context of orphan medicines designation in the European Union.

Orphanet journal of rare diseases·2014

Same author

Promoting the development of drugs against rare diseases: what more should be done?

Expert review of pharmacoeconomics & outcomes research·2012

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

A regulatory overview about rare diseases.

Jordi Llinares¹

¹European Medicines Agency, Canary Wharf, London, UK. jordi.llinares@ema.europa.eu

Advances in Experimental Medicine and Biology

|September 9, 2010

Summary

Orphan legislation provides incentives like scientific advice and market exclusivity, stimulating rare disease drug development. These measures have led to numerous designated orphan medicines and marketing authorizations, addressing unmet medical needs.

Area of Science:

Pharmacology
Regulatory Science
Medical Research

Background:

Drug development for rare diseases faces significant challenges due to limited interest and small patient populations.
Orphan legislation offers incentives to encourage research and development (R&D) for treatments, diagnostics, and preventive measures for rare conditions.
Regulatory bodies increasingly recognize the need for specific attention and tailored guidance for rare diseases.

Purpose of the Study:

To evaluate the impact of orphan legislation incentives on rare disease drug development.
To highlight the role of regulatory authorities in facilitating market access for orphan medicines.
To identify future needs for collaborative research and knowledge networking in rare disease drug development.

Main Methods:

More Related Videos

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

Related Experiment Videos

Last Updated: Jun 9, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

Review of existing orphan legislation and its incentive mechanisms (e.g., scientific advice, grants, market exclusivity, fee reductions).
Analysis of data on designated orphan medicines and marketing authorizations in the US.
Examination of regulatory pathways for rare disease products, including conditional and exceptional circumstances authorizations.

Main Results:

Orphan incentives have demonstrably stimulated R&D for new rare disease products.
In the US, nearly 2000 products received orphan designation, with approximately 340 gaining marketing authorization.
Regulatory authorities have implemented flexible pathways to accommodate data limitations in rare disease drug approval.

Conclusions:

Incentives provided by orphan legislation are effective in promoting the development of medicines for rare diseases.
Regulatory flexibility and tailored guidance are crucial for bringing orphan drugs to market.
Future efforts should focus on enhancing scientific networking and research collaboration to overcome data generation challenges in rare diseases.